Zephyrm Biotech
Pioneering stem cell therapeutics to tackle challenges beyond the reach of traditional medicines and treatments.
Pioneering stem cell therapeutics to tackle challenges beyond the reach of traditional medicines and treatments.
Zephyrm Biotech is a biotechnology startup founded in 2018 that is pioneering stem cell therapeutics. Their slogan "Pioneering stem cell therapeutics to tackle challenges beyond the reach of traditional medicines and treatments" reflects their commitment to breaking new ground in the medical field. The company focuses on developing stem cell therapeutics and promotes stem cell clinical use and industrial transformation, allowing clients to address needs that normal medicines and treatment methods cannot. In their most recent funding round, Zephyrm Biotech secured a CNY200.00M Series B investment on 17th April 2023 from CCB Trust. This investment underlines the confidence of investors in the potential of the company and its innovative approach to addressing medical challenges through stem cell therapeutics. As the company continues to expand and make strides in the biotechnology industry, it will be interesting to see how it utilizes this investment to further its pioneering work in the field of stem cell therapeutics.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | CNY200.00M | 1 |
|
17 Apr 2023 |
No recent news or press coverage available for Zephyrm Biotech.
We care about your data, and we'd love to use cookies make your experience better.
